The Serotonin Syndrome Market is size is anticipated to reach USD 0.72 Billion by 2032 at 4.9% CAGR during the forecast period 2023-2032. There has been a growth in the assumption of serotonin syndrome in several industries such as clinic use, and hospital use. Different trade shows and reveals have also helped serotonin syndrome manufacturing companies to enlarge their consumer base and contribute remarkably to the rise of the serotonin syndrome market.
FINTEPLA® (fenfluramine) oral solution CIV has been authorized in the United States by the U.S. Food and Drug Administration (FDA) in March 2022, according to UCB, a global biopharmaceutical company. The Food and Drug Administration (FDA) has approved the use of this medication to treat seizures associated with Lennox-Gastaut syndrome in patients aged two years and older. In addition, the FDA has granted pediatric exclusivity for the product. It has already been approved for the treatment of seizures associated with Dravet syndrome in patients aged two years and older in the United States and the European Union. The Risk Evaluation and Mitigation Strategy (REMS) Program is the restricted distribution program through which Fenfluramine for LGS is available in the United States. Fenfluramine has been shown to be effective in treating the most challenging seizure types, such as drop seizures, which result in an abrupt loss of muscle tone, a limp, and a fall to the ground with a high probability of injury. Fenfluramine differs from and complements current seizure medications in terms of its mechanism of action, and it can be administered without disrupting existing antiseizure regimens. In the global placebo-controlled phase 3 clinical trial, patients with LGS experienced numerically greater improvements on the Clinical Global Impression scale (CG-I) when they were administered fenfluramine.
In September 2023, Fabre-Kramer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development of innovative therapies to address unmet requirements in neurology and psychiatry, is pleased to announce that the U.S. Exxua™ (gepirone hydrochloride extended-release tablets) has been approved by the Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults. Exxua is the first and only antidepressant to be approved with a novel mechanism of action that selectively targets the serotonin 1A receptor, a key regulator of mood and emotion. It represents a new class of antidepressant. Exxua has been demonstrated to effectively alleviate depressive symptoms, and its approved labeling does not include any Warnings or Adverse Reactions regarding the potential for sexual dysfunction or weight gain in comparison to a placebo. It is anticipated that Exxua will be accessible in pharmacies by the beginning of 2024. In clinical trials, sexual side effects associated with EXXUA treatment were comparable to placebos and did not satisfy the incidence criteria for inclusion in the Adverse Reaction section of EXXUA's label. EXXUA also demonstrated an overall satisfactory safety profile, with no substantial adverse effects on liver function, blood pressure, pulse rate, or weight. Dizziness and nausea were the most frequently observed adverse events in clinical trials. These side effects were typically moderate, brief, and directly associated with dose escalations. They did not necessitate treatment discontinuation.
The main reason for the report is to provide a detailed analysis of the serotonin syndrome market relied on the types of supportive care, gastrointestinal decontamination, serotonin antagonists, and geography. The report shows detailed information regarding the main factors controlling the growth of the serotonin syndrome market. The report also shows a detailed review of the serotonin syndrome value chain and inspects the market trends.
Serotonin Syndrome Market Segmentation
The serotonin syndrome market is segmented on the basis of drug treatment, and end users.
Based on drug treatment, the market has been segmented as serotonin antagonists, supportive care (Muscle relaxants, the control of autonomic instability, anti-hyperthermics, antihypertensive and others.
Based on the end users, the market has been segmented as hospitals, point of care and others.
US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global serotonin syndrome diagnosis and treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.
Key players profiled in the report are:
The report for Serotonin syndrome market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Intended Audience
Recent Development
The sudden outbreak of the covid-19 pandemic across the world had led to the implementation of strict lockdown regulations across various nations ensuring a disruption in import and export activities of serotonin syndrome. The global economy has been affected by the covid-19 in three primary ways, by directly affecting ultimatum and production, by making market disruption and supply chain, and its financial impact on firms and financial markets. Our researchers observing the situation across the world explains that the market will create remunerative views for producers post covid-19 pandemic. The reports projects to give an additional illustration of the recent scenario, economic declination, and covid-19 impact on the overall industry. Serotonin syndrome market 2021 research report gives an important analysis of the market status of the serotonin syndrome manufacturers with the best facts and meaning, figures, definitions, SWOT analysis, expert opinions, and the recent developments across the world.
Report Scope:| Attribute/Metric | Details |
| Market Size 2032 | USD 0.72 Billion |
| CAGR | 4.9% (2023-2032) |
| Base Year | 2021 |
| Forecast Period | 2023-2032 |
| Historical Data | 2020 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Drug Treatment, and End Users |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | AstraZeneca Plc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc. and Sanofi S.A., Ciron Drugs & Pharmaceuticals Pvt. Ltd. and others |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | Growing advancements in the development of novel drugs· Growing health infrastructure in several nations |
Serotonin Syndrome Market Highlights:
Frequently Asked Questions (FAQ) :
Serotonin syndrome market is expected to exhibit a CAGR of 4.9% from 2023 to 2032.
Serotonin syndrome market size can reach USD 0.72 Billion by 2032.
North America can dominate the global serotonin syndrome market till 2032.
Asia Pacific (APAC) has the highest potential for growth in the global serotonin syndrome market.
AstraZeneca Plc., Johnson & Johnson, Merck & Co., Inc., Forest Laboratories Inc., Pfizer, Inc., Sanofi S., Eli Lilly and Company, Ciron Drugs & Pharmaceuticals Pvt. Ltd., and GlaxoSmithKline plc are notable players of the global serotonin syndrome market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
